Drug Profile


Alternative Names: RU-8811; SPI-8811

Latest Information Update: 13 Jul 2016

Price : $50

At a glance

  • Originator Sucampo Pharmaceuticals
  • Class Fatty acids; Small molecules
  • Mechanism of Action Chloride channel agonists; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Gastro-oesophageal reflux; Inflammatory bowel diseases; Non-alcoholic steatohepatitis; NSAID-induced ulcer; Portal hypertension; Stomatitis; Wounds

Most Recent Events

  • 11 Jul 2016 Discontinued - Preclinical for Wounds in USA (Topical)
  • 11 Jul 2016 Discontinued - Phase-II for NSAID-induced ulcer (Prevention) in USA (PO)
  • 11 Jul 2016 Discontinued - Preclinical for Inflammatory bowel disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top